Background
Semax is a synthetic heptapeptide analog of ACTH(4-7) with the sequence Met-Glu-His-Phe-Pro-Gly-Pro, developed in Russia by the Institute of Molecular Genetics. It is approved in Russia and Ukraine for treatment of ischemic stroke and cognitive impairment.
Semax’s primary mechanism involves upregulation of BDNF (brain-derived neurotrophic factor) and its receptor TrkB, providing neuroprotective and neuroplasticity-enhancing effects. This study combined clinical data from post-stroke patients with mechanistic animal data.
Methods
Clinical component: Prospective, controlled study in 190 ischemic stroke patients. Semax 0.1% nasal spray 2 mg/day × 10 days vs. standard neuroprotective therapy. Primary outcome: NIHSS (National Institutes of Health Stroke Scale) improvement.
Preclinical: Rat models of ischemia; hippocampal BDNF and TrkB expression measured by ELISA and RT-PCR.
Key Findings
| Outcome | Semax Group | Control |
|---|---|---|
| NIHSS improvement at day 10 | Significant (p<0.01) | Less improvement |
| Cognitive score (MoCA-like) | Significant improvement | Modest improvement |
| Functional recovery at 1 month | 65% good outcome | 48% good outcome |
| BDNF (rat hippocampus) | +180% vs. vehicle | — |
| TrkB expression | Significantly upregulated | — |
Clinical Significance
The clinical stroke data, while from a single-country non-blinded study, is consistent with Semax’s pharmacological mechanism and its approval status in Russia. The BDNF/TrkB mechanistic data provides biological plausibility for Semax’s nootropic and neuroprotective effects.
Off-label use of Semax for cognitive enhancement, ADHD management, and neurological optimization has expanded considerably in Western countries based on this and similar Russian clinical literature.
Limitations
- Clinical data from Russian literature; study designs typically less rigorous than Western RCTs
- No blinding described in the clinical component
- Regulatory approval is regional (Russia/Ukraine); FDA has not reviewed
- Nasal bioavailability in humans is variable and poorly characterized
- Limited English-language peer review of the primary clinical data